Diphenoxylate
Atropine / Diphenoxylate, Lomotil (diphenoxylate) is a small molecule pharmaceutical. Diphenoxylate was first approved as Lomotil on 1982-01-01. It is used to treat diarrhea in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Combinations
Lomotil (generic drugs available since 1982-01-01, discontinued: Colonaid, Di-atro, Lo-trol, Logen, Lomanate, Lonox, Low-quel)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| diphenoxylate hcl and atropine sulfate | ANDA | 2010-03-24 |
| diphenoxylate hydrochloride and atropine sulfate | ANDA | 2024-02-01 |
| direct rx | ANDA | 2015-08-05 |
| lomotil | New Drug Application | 2023-09-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diarrhea | HP_0002014 | D003967 | R19.7 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Short bowel syndrome | D012778 | — | K90.82 | — | — | 2 | — | — | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diphenoxylate |
| INN | diphenoxylate |
| Description | Diphenoxylate is a piperidinecarboxylate ester that is the ethyl ester of difenoxin. It has a role as an antidiarrhoeal drug. It is a nitrile, a piperidinecarboxylate ester, a tertiary amine and an ethyl ester. It is functionally related to a difenoxin. |
| Classification | Small molecule |
| Drug class | Opioid Antidiarrheal |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 915-30-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201294 |
| ChEBI ID | 4639 |
| PubChem CID | 13505 |
| DrugBank | DB01081 |
| UNII ID | 73312P173G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Diphenoxylate
+
Atropine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,404 documents
View more details
Safety
Black-box Warning
Black-box warning for: Direct rx
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,513 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use